RPA2

Across TCGA pan-cancer cohorts, RPA2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPA2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where RPA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.818	0.406	<.001	41	view →
LUAD	DFS	Median	All	0.905	0.379	<.001	32	view →
PDAC	DFS	Tertile	All	0.468	0.316	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPA2–CCRCC (DFS)

Open the CCRCC breakdown →